Comparative Pharmacodynamic Bioequivalence Study of Enoxaparin Sodium 100 mg/1 mL Solution for Injection in Prefilled Syringe in Healthy Volunteers Under Fasting Conditions
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1565 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Naba Kumar Talukdar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Department, Biostatistics Department, Accutest Research Laboratories Private Limited, Navi Mumbai, India. Hauptthemen laut MEDLINE: Enoxaparin, Anticoagulants, Factor Xa Inhibitors. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
This study evaluated the bioequivalence of enoxaparin sodium 100 mg/1 mL solution for injection in a prefilled syringe manufactured by a generic company was compared with the reference product of the same dosage form, in healthy adult volunteers under fasting conditions. The comparison focused on pharmacodynamic (PD) parameters. This open‐label, randomized, balanced, 2‐treatment, 2‐period, single‐dose, crossover study involved 60 healthy volunteers. No serious adverse events were reported. Chromogenic assay techniques were used for sample analysis. The linearity range for PD parameters was from 0.100 to 0.800 IU/mL for anti‐factor IIa activity, from 0.100 to 0.800 IU/mL for anti‐factor Xa activity, and from 750.000 to 10,000.000 pg/mL for tissue factor pathway inhibitor quantification. Statistical analysis was conducted using SAS software Version 9.4. The PD parameters evaluated included maximum observed activity concentration, area under the effect curve from time 0 to time t, median time to maximum concentration, and terminal elimination half‐life for anti‐factor Xa and anti‐factor IIa activity. The 95% confidence intervals for the geometric mean ratio of log‐transformed PD parameters between the test and reference products for anti‐factor Xa and anti‐factor IIa activities were within the range of 80%‐125%. It was concluded that the test formulation is bioequivalent to the reference formulation of 100 mg/1 mL solution for injection in a prefilled syringe, under fasting conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Department, Biostatistics Department, Accutest Research Laboratories Private Limited, Navi Mumbai, India.
- Biologics Bioanalytical Department, Accutest Biologics Private Limited, Navi Mumbai, India.
- Research, Development and Innovation Department, Blau Farmacêutica S.A., São Paulo, Brazil.
Zitieren
APA
Talukdar, N. K., Sonar, S., Pal, N., & Silva, U. (2025). Comparative Pharmacodynamic Bioequivalence Study of Enoxaparin Sodium 100 mg/1 mL Solution for Injection in Prefilled Syringe in Healthy Volunteers Under Fasting Conditions. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1565
Vancouver
Talukdar NK, Sonar S, Pal N, Silva U. Comparative Pharmacodynamic Bioequivalence Study of Enoxaparin Sodium 100 mg/1 mL Solution for Injection in Prefilled Syringe in Healthy Volunteers Under Fasting Conditions. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1565
BibTeX
@article{Talukdar2025,
author = {Talukdar, Naba Kumar and Sonar, Shailesh and Pal, Nisha and Silva, Uilberson},
title = {Comparative Pharmacodynamic Bioequivalence Study of Enoxaparin Sodium 100 mg/1 mL Solution for Injection in Prefilled Syringe in Healthy Volunteers Under Fasting Conditions},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1565}
}
EUVIMED